Kura Oncology, Inc. (NASDAQ:KURA) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have received an average rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $29.20.

Several equities analysts have commented on KURA shares. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Kura Oncology in a research report on Monday, August 12th. JMP Securities restated a “market outperform” rating and issued a $32.00 price target on shares of Kura Oncology in a report on Monday, August 12th. Wedbush reaffirmed an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a research note on Friday, August 9th. StockNews.com cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, August 22nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a research report on Monday, September 9th.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. nVerses Capital LLC purchased a new stake in shares of Kura Oncology in the 3rd quarter worth approximately $25,000. SG Americas Securities LLC purchased a new stake in Kura Oncology during the first quarter worth $110,000. Quarry LP bought a new stake in Kura Oncology during the 2nd quarter valued at $196,000. Saxon Interests Inc. purchased a new stake in shares of Kura Oncology during the 1st quarter worth $201,000. Finally, Entropy Technologies LP bought a new stake in Kura Oncology during the first quarter valued at about $218,000.

Kura Oncology Price Performance

NASDAQ:KURA opened at $18.00 on Wednesday. The business’s 50-day moving average is $19.51 and its 200 day moving average is $20.19. Kura Oncology has a 12 month low of $7.41 and a 12 month high of $24.17. The company has a current ratio of 14.94, a quick ratio of 14.94 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $1.37 billion, a P/E ratio of -8.29 and a beta of 0.84.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.04. The company’s revenue was up .0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.53) EPS. On average, equities research analysts forecast that Kura Oncology will post -2.45 earnings per share for the current fiscal year.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.